Related Experiment Videos
Cytokines levels in prostate adenocarcinomas
Maria Bălăşoiu1, Adriana Turculeanu, Carmen Avrămescu
1Department of Microbiology-Immunology, University of Medicine and Pharmacy of Craiova. turculeanu_balasoiu@yahoo.com
Summary
This study found that advanced prostate cancer (stages III and IV) shows decreased Interleukin-2 (IL-2) and increased pro-inflammatory cytokines Interleukin-6 (IL-6) and Tumor Necrosis Factor-alpha (TNF-alpha). These changes correlate with disease progression and reduced immune response.
Area of Science:
- Oncology
- Immunology
- Biochemistry
Background:
- Prostate adenocarcinoma is a common cancer in men.
- Immune response plays a role in cancer progression.
- Cytokines like IL-2, IL-6, and TNF-alpha are key immune mediators.
Purpose of the Study:
- To determine the levels of IL-2, IL-6, and TNF-alpha in prostate cancer patients across different stages.
- To correlate cytokine levels with prostate cancer stage and disease evolution.
Main Methods:
- Quantitative ELISA was used to measure cytokine levels.
- Sixty patients with prostate adenocarcinoma (stages II, III, and IV) were included.
Main Results:
- Stage II prostate cancer showed normal IL-2 and slightly increased IL-6 and TNF-alpha.
- Stages III and IV prostate cancer exhibited very low IL-2 and significantly elevated IL-6 and TNF-alpha.
- High pro-inflammatory cytokine levels correlated with disease progression.
Conclusions:
- Decreased IL-2 levels in advanced prostate cancer are associated with a diminished immune response.
- Elevated IL-6 and TNF-alpha indicate a pro-inflammatory state that parallels disease advancement in prostate cancer.